These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 15681404)

  • 1. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.
    Oumouna M; Mapletoft JW; Karvonen BC; Babiuk LA; van Drunen Littel-van den Hurk S
    J Virol; 2005 Feb; 79(4):2024-32. PubMed ID: 15681404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus.
    Mapletoft JW; Oumouna M; Townsend HG; Gomis S; Babiuk LA; van Drunen Littel-van den Hurk S
    Virology; 2006 Sep; 353(2):316-23. PubMed ID: 16828832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice.
    Kovacs-Nolan J; Mapletoft JW; Lawman Z; Babiuk LA; van Drunen Littel-van den Hurk S
    J Gen Virol; 2009 Aug; 90(Pt 8):1892-1905. PubMed ID: 19386785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.
    Mapletoft JW; Latimer L; Babiuk LA; van Drunen Littel-van den Hurk S
    Clin Vaccine Immunol; 2010 Jan; 17(1):23-35. PubMed ID: 19864487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection.
    Mapletoft JW; Oumouna M; Kovacs-Nolan J; Latimer L; Mutwiri G; Babiuk LA; van Drunen Littel-van den Hurk S
    J Gen Virol; 2008 Jan; 89(Pt 1):250-260. PubMed ID: 18089749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of antiviral CD8 T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection.
    Antonis AF; Claassen EA; Hensen EJ; de Groot RJ; de Groot-Mijnes JD; Schrijver RS; van der Most RG
    Vaccine; 2006 Mar; 24(10):1551-61. PubMed ID: 16310293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
    Ioannou XP; Gomis SM; Karvonen B; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
    Vaccine; 2002 Nov; 21(1-2):127-37. PubMed ID: 12443671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchoalveolar lavage fluid and disease outcome in experimentally infected calves.
    Kalina WV; Woolums AR; Gershwin LJ
    Vaccine; 2005 Aug; 23(37):4625-30. PubMed ID: 15967545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon gamma production during bovine respiratory syncytial virus (BRSV) infection is diminished in calves vaccinated with formalin-inactivated BRSV.
    Woolums AR; Singer RS; Boyle GA; Gershwin LJ
    Vaccine; 1999 Mar; 17(11-12):1293-7. PubMed ID: 10195762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration.
    Ellis J; Gow S; West K; Waldner C; Rhodes C; Mutwiri G; Rosenberg H
    J Am Vet Med Assoc; 2007 Jan; 230(2):233-43. PubMed ID: 17223757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bovine respiratory syncytial virus-specific immune responses in calves after inoculation with commercially available vaccines.
    Ellis JA; Hassard LE; Morley PS
    J Am Vet Med Assoc; 1995 Feb; 206(3):354-61. PubMed ID: 7751246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.
    Fonseca DM; Silva CL; Paula MO; Soares EG; Marchal G; Horn C; Bonato VL
    Immunology; 2007 Aug; 121(4):508-17. PubMed ID: 17433075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocyte activity and cytokine expression in calves vaccinated with formalin-inactivated bovine respiratory syncytial virus prior to challenge.
    Woolums AR; Gunther RA; McArthur-Vaughan K; Anderson ML; Omlor A; Boyle GA; Friebertshauser KE; McInturff PS; Gershwin LJ
    Comp Immunol Microbiol Infect Dis; 2004 Jan; 27(1):57-74. PubMed ID: 14656542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves.
    Ellis JA; West KH; Waldner C; Rhodes C
    Can Vet J; 2005 Feb; 46(2):155-62. PubMed ID: 15825518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in 3-week-old calves experimentally challenged with BRSV.
    Vangeel I; Antonis AF; Fluess M; Riegler L; Peters AR; Harmeyer SS
    Vet J; 2007 Nov; 174(3):627-35. PubMed ID: 17169592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo.
    Zhang L; Tian X; Zhou F
    Int Immunopharmacol; 2007 Dec; 7(13):1732-40. PubMed ID: 17996683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of an inactivated respiratory syncytial virus vaccine in calves.
    Ellis J; West K; Konoby C; Leard T; Gallo G; Conlon J; Fitzgerald N
    J Am Vet Med Assoc; 2001 Jun; 218(12):1973-80. PubMed ID: 11417745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.